<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.3.47">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>When Precision Therapy Creates Inprecise Choices</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="Manuscript_files/libs/clipboard/clipboard.min.js"></script>
<script src="Manuscript_files/libs/quarto-html/quarto.js"></script>
<script src="Manuscript_files/libs/quarto-html/popper.min.js"></script>
<script src="Manuscript_files/libs/quarto-html/tippy.umd.min.js"></script>
<script src="Manuscript_files/libs/quarto-html/anchor.min.js"></script>
<link href="Manuscript_files/libs/quarto-html/tippy.css" rel="stylesheet">
<link href="Manuscript_files/libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="Manuscript_files/libs/bootstrap/bootstrap.min.js"></script>
<link href="Manuscript_files/libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="Manuscript_files/libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">


</head>

<body class="fullcontent">

<div id="quarto-content" class="page-columns page-rows-contents page-layout-article">

<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title">When Precision Therapy Creates Inprecise Choices</h1>
<p class="subtitle lead">Antifungal prophyalxis in the era or targeted therapy for acute myelogenoys leukemia</p>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<p>Russell E. Lewis, Pharm.D.<sup>1</sup></p>
<p>Marta Stanzani, M.D., Ph.D.<sup>2</sup></p>
<p><sup>1</sup>Associate Professor of Medicine, Department of Molecular Medicine, University of Padua, Padua, Italy:ORCID ID 000-0002-2002-4339</p>
<p><sup>2</sup>Director of Hematopoietic Stem Cell Transplantation and Cellular Therapy, &nbsp; Hematology Unit, Ca’ Foncello Hospital,&nbsp; AULSS 2- Marca Trevigana, Treviso, Italy:ORCID ID:000-0003-1569-3447</p>
<section id="section" class="level2">
<h2 class="anchored" data-anchor-id="section"></h2>
</section>
<section id="keywords" class="level2">
<h2 class="anchored" data-anchor-id="keywords">Keywords</h2>
</section>
<section id="competing-interests" class="level2">
<h2 class="anchored" data-anchor-id="competing-interests">Competing interests</h2>
</section>
<section id="section-1" class="level2">
<h2 class="anchored" data-anchor-id="section-1"></h2>
</section>
<section id="abstract" class="level2">
<h2 class="anchored" data-anchor-id="abstract">Abstract</h2>
<p>150-250 words</p>
</section>
<section id="introduction" class="level2">
<h2 class="anchored" data-anchor-id="introduction">Introduction</h2>
<p>Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the proliferation of myeloid blasts or progranulocytes that fail to undergo normal differentiation <span class="citation" data-cites="newell_cook21a">[<a href="#ref-newell_cook21a" role="doc-biblioref">1</a>]</span>. It is the most common acute leukemia is older adults and historically associated with 5-year survival rates less than 10-15% <span class="citation" data-cites="kantarjian_etal21b">[<a href="#ref-kantarjian_etal21b" role="doc-biblioref">2</a>]</span>. The standard remission-induction chemotherapy for AML in use for over 40 years combines cytarabine and an anthracycline that results in severe and prolonged neutropenia, which places patients at high risk for developing life-threatening invasive fungal diseases (IFDs) <span class="citation" data-cites="taplitz_etal18">[<a href="#ref-taplitz_etal18" role="doc-biblioref">3</a>]</span> Beyond the direct mortality of these infections, IFDs can jeopardize the timing and intensity of subsequent chemotherapy treatment cycles <span class="citation" data-cites="girmenia2014a even2011">[<a href="#ref-girmenia2014a" role="doc-biblioref">4</a>,<a href="#ref-even2011" role="doc-biblioref">5</a>]</span> or stem cell transplantation <span class="citation" data-cites="cordonnier_etal95 offner_etal98">[<a href="#ref-cordonnier_etal95" role="doc-biblioref">6</a>,<a href="#ref-offner_etal98" role="doc-biblioref">7</a>]</span>increasing the patient’s risk for leukemia relapse. As a result, antifungal prophylaxis, most commonly with posaconazole, has become a standard of care in many centres to reduce the risk of fungal fungal infection during remission-induction chemotherapy <span class="citation" data-cites="maertens_etal18 cornely2007J">[<a href="#ref-maertens_etal18" role="doc-biblioref">8</a>,<a href="#ref-cornely2007J" role="doc-biblioref">9</a>]</span></p>
<p>Progress in the knowledge of the biology and therapy of acute myeloid leukemia (AML) has evolved at a rapid pace over the last two decades. High resolution cytogenetics and next-generation sequencing have better defined the molecular drivers or lekemogenesis and disease progression sparking an explosion in novel “targeted thearpies” <span class="citation" data-cites="kantarjian2021">[<a href="#ref-kantarjian2021" role="doc-biblioref">10</a>]</span>. Most of these new therapies are represented by small molecule kinase inhibitors (SMKIs) that target aberrant signalling pathways that arise form somatic mutations in leukemic cells<span class="citation" data-cites="kantarjian_etal21">[<a href="#ref-kantarjian_etal21" role="doc-biblioref">11</a>]</span>. Targeted therapies are now being incorporated in virtually every treatment phase of AML, and increasingly are used in place of more toxic standard chemotherapy regimens in older adults who in the past were only candidates for pallative care or hospise care <span class="citation" data-cites="kantarjian_etal22">[<a href="#ref-kantarjian_etal22" role="doc-biblioref">12</a>]</span>.</p>
<p>Despite the promise of these new therapies, their clinical use in patients with AML is often complicated by drug interactions affecting their metabolic clearance through the CYP3A4/5 pathway <span class="citation" data-cites="bruggemann2022">[<a href="#ref-bruggemann2022" role="doc-biblioref">13</a>]</span> Co-administration of SMKIs with mould-active triazoles such as posaconazole, can result in excessive drug exposures and serious toxicities without dosage adjustment of the SMKIs or discontinuation of the triazole. Therefore, clinicians are often faced with the prospect of (i) potentially stopping triazole prophylaxis to avoid interactions with the SMKI; (ii) switching to an alternative antifungal prophylaxis without CYP3A4/5 interactions; (iii) empirically reducing the dose of the SMKI to account for the effect of triazole CYP3A4/5 inhibition; and (iv) continuing both the SMKI and triazole atful dose and monitoring the patient carefully for toxicity. Each of these choices are associated with potential risks to patient and must be weighed carefully depending on the treatment setting and resources available for diagnostic testing and therapeutic drug monitoring.</p>
<p>In this review, we address these four questions for the three most common class of prescribed SMKIs-venetoclax, FLT3 inhibitors (midostaurin, gilteritinib, quizartinib) and IDH inhibitors (ivosidenib, enasidenib). We will specifically focus on recent data examining what is known about the potential risks for IFD with SMKIs used in AML treatment that define the need for prophylaxis, what are the advantages and disadvantages of using non-triazole based prophylaxis, what is known about the safety of empiric dose adjustments for SMKIs, and what the are the risks giving triazole with full-dose SMKI therapy.</p>
</section>
<section id="should-triazole-prophylaxis-be-stopped" class="level2">
<h2 class="anchored" data-anchor-id="should-triazole-prophylaxis-be-stopped">Should triazole prophylaxis be stopped?</h2>
<p><br>
Should we consider non-triazole based primary prophylaxis?</p>
<p><br>
</p>

</section>

<div id="quarto-appendix" class="default"><section class="quarto-appendix-contents" role="doc-bibliography"><h2 class="anchored quarto-appendix-heading">References</h2><div id="refs" class="references csl-bib-body" role="doc-bibliography">
<div id="ref-newell_cook21a" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Newell LF, Cook RJ. <a href="https://doi.org/10.1136/bmj.n2026">Advances in acute myeloid leukemia</a>. BMJ <strong>2021</strong>; 375. </div>
</div>
<div id="ref-kantarjian_etal21b" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Kantarjian HM, Jabbour E, Short NJ, et al. <a href="https://doi.org/10.1016/j.clml.2021.05.016">Acute <span>Myeloid Leukemia</span>: <span>Historical Perspective</span> and <span>Progress</span> in <span>Research</span> and <span>Therapy Over</span> 5 <span>Decades</span>.</a> Clinical Lymphoma, Myeloma &amp; Leukemia <strong>2021</strong>; 21:580–597. </div>
</div>
<div id="ref-taplitz_etal18" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Taplitz RA, Kennedy EB, Bow EJ, et al. <a href="https://doi.org/10.1200/JCO.18.00374">Antimicrobial <span>Prophylaxis</span> for <span>Adult Patients With Cancer-Related Immunosuppression</span>: <span>ASCO</span> and <span>IDSA Clinical Practice Guideline Update</span></a>. Journal of clinical oncology: official journal of the American Society of Clinical Oncology <strong>2018</strong>; :JCO1800374. </div>
</div>
<div id="ref-girmenia2014a" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Girmenia C, Micozzi A, Piciocchi A, et al. <a href="https://doi.org/10.1016/j.leukres.2014.01.007">Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia</a>. Leukemia research <strong>2014</strong>; 38:469–474. </div>
</div>
<div id="ref-even2011" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Even C, Bastuji-Garin S, Hicheri Y, et al. <a href="https://doi.org/10.3324/haematol.2010.030825">Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: A case-control study</a>. Haematologica <strong>2011</strong>; 96:337–341. </div>
</div>
<div id="ref-cordonnier_etal95" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Cordonnier C, Beaune J, Offner F, Marinus A, Ljungman P, Meunier F. <a href="https://www.ncbi.nlm.nih.gov/pubmed/7581159">Aspergillosis prior to bone marrow transplantation. <span>Infectious Diseases Working Party</span> of the <span>EBMT</span> and the <span>EORTC Invasive Fungal Infections Cooperative Group</span></a>. Bone Marrow Transplantation <strong>1995</strong>; 16:323–324. </div>
</div>
<div id="ref-offner_etal98" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Offner F, Cordonnier C, Ljungman P, et al. <a href="https://doi.org/10.1086/520274">Impact of previous aspergillosis on the outcome of bone marrow transplantation</a>. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America <strong>1998</strong>; 26:1098–1103. </div>
</div>
<div id="ref-maertens_etal18" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Maertens JA, Girmenia C, Brüggemann RJ, et al. <a href="https://doi.org/10.1093/jac/dky286">European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the <span>European Conference</span> on <span>Infections</span> in <span>Leukaemia</span></a>. The Journal of antimicrobial chemotherapy <strong>2018</strong>; </div>
</div>
<div id="ref-cornely2007J" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Cornely OA, Maertens J, Winston DJ, et al. <a href="https://doi.org/10.1056/NEJMoa061094">Posaconazole vs. <span>Fluconazole</span> or <span>Itraconazole Prophylaxis</span> in <span>Patients</span> with <span>Neutropenia</span></a>. The New England journal of medicine <strong>2007</strong>; 356:348–359. </div>
</div>
<div id="ref-kantarjian2021" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Kantarjian H, Short NJ, DiNardo C, et al. <a href="https://doi.org/10.1016/S2352-3026(21)00270-2">Harnessing the benefits of available targeted therapies in acute myeloid leukaemia</a>. The Lancet Haematology <strong>2021</strong>; 8:e922–e933. </div>
</div>
<div id="ref-kantarjian_etal21" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Kantarjian H, Kadia T, DiNardo C, et al. <a href="https://doi.org/10.1038/s41408-021-00425-3">Acute myeloid leukemia: Current progress and future directions</a>. Blood Cancer Journal <strong>2021</strong>; 11:1–25. </div>
</div>
<div id="ref-kantarjian_etal22" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Kantarjian HM, Jain N, Garcia-Manero G, et al. <a href="https://doi.org/10.1002/cncr.33933">The cure of leukemia through the optimist’s prism</a>. Cancer <strong>2022</strong>; 128:240–259. </div>
</div>
<div id="ref-bruggemann2022" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Brüggemann RJ, Verheggen R, Boerrigter E, et al. <a href="https://doi.org/10.1016/S2352-3026(21)00232-5">Management of drugdrug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs</a>. The Lancet Haematology <strong>2022</strong>; 9:e58–e72. </div>
</div>
</div></section></div></main>
<!-- /main column -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
</div> <!-- /content -->



</body></html>